Home > Products > CD64 & EGFR
> Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scFv-CH3)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scFv-CH3) (CAT#: BSFC-125)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scFv-CH3) contains two chains. The anti-CD64 scFv is fused to the Knob-CH3 domain via a hinge region and the same as the anti-EGFR scFv to the Hole-CH3 domain, or vice versa. The KIH CH3 domains can facilitate to form a heterodimer and this bivalent binding leads to improvement in avidity. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (scFv-CH3) (BSFC-125). Click the button below to contact us or submit your feedback about this product.